The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC

EP: 1.Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC

EP: 2.Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

EP: 3.Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

Now Viewing

EP: 4.The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC

Video content above is prompted by the following:

Quality of Life Considerations

Key Themes:

• Balance of Efficacy and Toxicity: Weighing survival benefits against treatment-related adverse events
• Patient Preferences: Discussion of Asian study data showing some patients prefer monotherapy with potentially shorter survival over combination therapy
• Prophylactic Management: Importance of supportive care measures to mitigate toxicity

Notable Insights:

• Dr Dietrich: “Quality of life is important when it comes to treatment-related toxicity. But...a significant drop occurs at the time of cancer progression, and that’s probably the quality-of-life impairment that I’m most struggling with.” He argued that quality and quantity of life often align rather than contradict.
• Dr Piotrowska: Highlighted the importance of supportive care data, noting “we’re seeing a lot of data from studies looking at ways to support patients better” including the COCOON study for dermatologic toxicities and the SKIPPirr regimen for preventing infusion-related reactions.